ERBB2 and cancer: Investigators utilized a retrovirus to insert HER CAR, TR2 antibody, and IL-15 genes into T cells, aiming to determine the maximum safe dose of TRAIL-R2 and HER2 bi-specific CAR T cells, monitor their persistence in the body, identify side effects, and evaluate their efficacy against HER2-expressing cancers.